Payment overview · 2025
General Payments
$611.83
32 reported records · 12 companies
Healthcare provider profile · identity verified
Isha Gupta, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SUN CITY, AZ · NPI 1255598744
Verified facts
What the public records show
CMS Open Payments records show Isha Gupta, MD received $611.83 in general payments during 2025 across 32 reported records.
GlaxoSmithKline, LLC. accounted for 28.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Trelegy Ellipta.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $174.96 | 28.6% | 12 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $96.47 | 15.8% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $53.04 | 8.7% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $49.70 | 8.1% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $46.48 | 7.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $40.86 | 6.7% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $29.08 | 4.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $28.54 | 4.7% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $27.58 | 4.5% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $25.72 | 4.2% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $25.46 | 4.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.94 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $611.83 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $154.75 | 8 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $96.47 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $49.70 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $46.48 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $35.71 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $29.08 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $28.54 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $27.58 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $25.72 | 1 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $25.46 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $22.09 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $20.21 | 4 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $20.21 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.77 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.77 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.77 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $17.33 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.10 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 47 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 34 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
34 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
47 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 250 | 79 |
| Levothyroxine Sodium | Levothyroxine Sodium | 206 | 63 |
| Gabapentin | Gabapentin | 169 | 59 |
| Amlodipine Besylate | Amlodipine Besylate | 152 | 49 |
| Lisinopril | Lisinopril | 128 | 39 |
| Montelukast Sodium | Montelukast Sodium | 118 | 49 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 105 | 17 |
| Omeprazole | Omeprazole | 94 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 94 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 92 | 31 |
| Metformin Hcl | Metformin Hcl | 91 | 31 |
| Simvastatin | Simvastatin | 91 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 79 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 68 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 68 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 62 | 22 |
| Losartan Potassium | Losartan Potassium | 62 | 27 |
| Alendronate Sodium | Alendronate Sodium | 56 | 18 |
| Celecoxib | Celecoxib | 56 | 18 |
| Donepezil Hcl | Donepezil Hcl | 54 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 50 | 20 |
| Tramadol Hcl | Tramadol Hcl | 49 | 14 |
| Alprazolam | Alprazolam | 47 | 17 |
| Mounjaro | Tirzepatide | 47 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 44 | 16 |
| Atenolol | Atenolol | 43 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 42 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 41 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 40 | 21 |
| Furosemide | Furosemide | 40 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 40 | 12 |
| Potassium Chloride | Potassium Chloride | 40 | 12 |
| Amoxicillin | Amoxicillin | 39 | 27 |
| Nifedipine Er | Nifedipine | 39 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 37 | 14 |
| Sertraline Hcl | Sertraline Hcl | 36 | 14 |
| Allopurinol | Allopurinol | 34 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | 15 |
| Trazodone Hcl | Trazodone Hcl | 33 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 32 | 11 |
| Cephalexin | Cephalexin | 30 | 27 |
| Prednisone | Prednisone | 30 | 17 |
| Metformin Hcl Er | Metformin Hcl | 29 | 11 |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 29 | suppressed |
| Lorazepam | Lorazepam | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 28 | 24 |
| Memantine Hcl | Memantine Hcl | 27 | 11 |
| Famotidine | Famotidine | 26 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 24 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 23 | suppressed |
| Azithromycin | Azithromycin | 22 | 20 |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Meloxicam | Meloxicam | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Eliquis | Apixaban | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 14 |
| Carvedilol | Carvedilol | 15 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Prolia | Denosumab | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Methadone Hcl | Methadone Hcl | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $611.83 · 32 records | GlaxoSmithKline, LLC. | ABRYSVO, AREXVY, COMIRNATY, Dexcom G6 Transmitter, FARXIGA, GEMTESA, INSPIRE, JARDIANCE, KISUNLA, Korlym, LEQVIO, MOUNJARO, PAXLOVID, PREVNAR 20, REPATHA, SHINGRIX, TRELEGY ELLIPTA, WaveWriter Alpha Prime 16, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error